Novo Nordisk tells STAT Metsera deal structure ‘consistent with antitrust laws’

After Daniel Guarnera, director of the bureau of competition at the FTC, wrote in a letter sent Tuesday to lawyers of Pfizer (PFE) and Metsera (MTSR) that if Novo Nordisk (NVO) first pays a large amount to acquire half of Metsera’s stock before seeking regulators’ review, then it may violate the act, Novo spokesperson Ambre James-Brown told STAT News: “The deal structure is consistent with antitrust laws. We are in a constructive dialogue with the FTC addressing the potential issues identified in its letter, and we remain confident that our agreement with Metsera is consistent with the HSR Act and antitrust laws.”